2018
DOI: 10.1016/j.preghy.2018.01.002
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics of amlodipine besylate at delivery and during lactation

Abstract: Amlodipine does cross the placenta in measurable quantities, but is not detected in breast milk or infant plasma at 24-48 h of life indicating that it is likely safe to use during the peripartum period.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 16 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…Both preparations were evaluated by confidence interval (CI, 1‐2α). If the 90% CI of the geometric mean ratio of C max and AUC 0‐72 h does not exceed the range of 80%‐125%, it can be judged that the test preparation and the reference preparation are bioequivalent 12 …”
Section: Methodsmentioning
confidence: 99%
“…Both preparations were evaluated by confidence interval (CI, 1‐2α). If the 90% CI of the geometric mean ratio of C max and AUC 0‐72 h does not exceed the range of 80%‐125%, it can be judged that the test preparation and the reference preparation are bioequivalent 12 …”
Section: Methodsmentioning
confidence: 99%
“…PK and bioequivalence evaluation of amlodipine besylate studied previously were fixed‐dose combinations in healthy subjects, in which amlodipine besylate was combined with losartan or orotate 1,7 . A PK study of amlodipine besylate was to evaluate amlodipine besylate in the peripartum period including quantities of placental passage, breast milk excretion, and infant exposure when the pregnant hypertensive women used the drug during pregnancy and the postpartum period 8 . However, PK and bioequivalence studies of amlodipine besylate in healthy adult subjects under fasting and postprandial conditions have not yet been reported.…”
mentioning
confidence: 99%